Back to Report Store Home

Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence

  • Published: May-2018
  • Report Code: GBIHC474MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 8

2 Introduction 11

2.1 Disease Introduction 11

2.2 Symptoms 12

2.3 Etiology 12

2.4 Pathophysiology 13

2.4.1 HER2 Testing 14

2.4.2 Other Biomarkers 15

2.5 Epidemiology 16

2.6 Diagnosis and Classification 18

2.7 Prognosis and Disease Staging 20

2.8 Treatment Options 21

2.8.1 Surgery and Radiation Therapy 22

2.8.2 Chemotherapy 23

2.8.3 Hormonal Therapies 23

2.8.4 Targeted Therapies 24

2.9 Treatment Guidelines 25

3 Marketed Products 29

3.1 Overview 29

3.1.1 Herceptin (trastuzumab) – Roche/Genentech 30

3.1.2 Perjeta (pertuzumab) – Roche/Genentech 34

3.1.3 Kadcyla (ado-trastuzumab emtansine) – Roche/Genentech 36

3.1.4 Tykerb/Tyverb (lapatinib ditosylate monohydrate) – Novartis 37

3.1.5 Ibrance (palbociclib) – Pfizer 39

3.1.6 Kisqali (ribociclib) – Novartis 42

3.1.7 Halaven (eribulin mesylate) – Eisai 44

3.1.8 Avastin (bevacizumab) – Roche/Genentech 45

3.1.9 Afinitor (everolimus) – Novartis 46

3.1.10 Abraxane (Nab-Paclitaxel) – Celgene 47

3.1.11 Ixempra (ixabepilone) – R-Pharm 49

3.1.12 Doxil/Caelyx (pegylated liposomal doxorubicin) – Johnson & Johnson 49

3.1.13 Faslodex (fulvestrant) – AstraZeneca 50

3.1.14 Tamoxifen 51

3.1.15 Aromatase Inhibitors (AIs) 52

3.2 Comparative Efficacy and Safety of Marketed Products 53

4 Pipeline Analysis 61

4.1 Overview 61

4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 62

4.2.1 Pipeline by Molecular Target 64

4.3 Promising Pipeline Molecules 66

4.3.1 Nerlynx (Neratinib) – Puma Biotechnology 66

4.3.2 Verzenio (abemaciclib) – Eli Lily 69

4.3.3 Lynparza (olaparib) – AstraZeneca 71

4.3.4 Talazoparib – Pfizer/BioMarin 73

4.3.5 Keytruda (pembrolizumab) – Merck & Co. 75

4.3.6 Tecentriq (atezolizumab) – Roche 77

4.3.7 Taselisib – Genentech 79

4.3.8 Alpelisib – Novartis 82

4.3.9 Margetuximab – MacroGenics 83

4.3.10 OBI-822/821 (adagloxad simolenin) – OBI Pharma 84

4.3.11 Utidelone (UTD-1) – Beijing Biostar Technologies 85

4.3.12 Pyrotinib (HTI1001/SHR1258) – Jiangsu Hengrui Medicine 86

4.3.13 Ipatasertib (RG-7440/GDC-0068) – Array Biopharma/Genentech 87

4.3.14 Epidaza (Tucidinostat/ HBI8000/ CS055) – Chipscreen Biosciences 87

4.3.15 BAT8001 – Bio-Thera Solutions 88

4.4 Comparative Efficacy and Safety of Pipeline Products 89

4.5 Product Competitiveness Framework 91

5 Clinical Trial Analysis 94

5.1 Failure Rate 94

5.1.1 Overall Failure Rate 94

5.1.2 Failure Rate by Phase and Molecule Type 96

5.1.3 Failure Rate by Phase and Molecule Target 97

5.2 Clinical Trial Duration 98

5.2.1 Clinical Trial Duration by Molecule Type 98

5.2.2 Clinical Trial Duration by Molecular Target 99

5.3 Clinical Trial Size 100

5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 100

5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 102

5.4 Competitive Clinical Trials Metrics Analysis 104

6 Multi-scenario Forecast 106

6.1 Overview 106

6.2 Asia-Pacific Market 107

6.3 India 110

6.3.1 Treatment Usage Patterns 110

6.3.2 Annual Cost of Therapy 111

6.3.3 Market Size 112

6.4 China 113

6.4.1 Treatment Usage Patterns 113

6.4.2 Annual Cost of Therapy 115

6.4.3 Market Size 116

6.5 Australia 118

6.5.1 Treatment Usage Patterns 118

6.5.2 Annual Cost of Therapy 119

6.5.3 Market Size 120

6.6 South Korea 122

6.6.1 Treatment Usage Patterns 122

6.6.2 Annual Cost of Therapy 123

6.6.3 Market Size 124

6.7 Japan 125

6.7.1 Treatment Usage Patterns 125

6.7.2 Annual Cost of Therapy 126

6.7.3 Market Size 128

7 Drivers and Barriers 130

7.1 Drivers 130

7.1.1 Increased Uptake of Targeted and Combination Therapies for Breast Cancer 130

7.1.2 Increasing Aging Population and Incident Cases of Breast Cancer 130

7.1.3 Prolonged Treatment Duration 131

7.1.4 Expansion of Branded Therapies into the Early Disease Regimen 131

7.1.5 Diversified Healthcare Reform and Insurance System to Boost Market Growth 131

7.2 Barriers 132

7.2.1 Usage of Surgical Therapies at Early Stage Reduces Drug Treatment Rate 132

7.2.2 Multiple Drugs to Lose Patent Protection in the Forecast Period 132

7.2.3 Delayed Presentation of Symptoms, Lack of Access and Awareness to Hamper Proper Treatment 133

7.2.4 High Level of Competition 133

7.2.5 Drug Pricing Reforms 133

7.2.6 Problems with the Reimbursement of Premium-Priced Therapeutics will Limit their Uptake 134

8 Deals and Strategic Consolidations 135

8.1 Licensing Deals 135

8.1.1 Deals by Region and Value 135

8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 136

8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 137

8.1.4 Key Licensing Deals 139

8.2 Co-development Deals 142

8.2.1 Deals by Region and Value 142

8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 143

8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 144

8.2.4 Key Co-development Deals 146

9 Appendix 148

9.1 All Pipeline Drugs by Stage of Development 148

9.1.1 Discovery 148

9.1.2 Preclinical 154

9.1.3 IND/CTA- filed 176

9.1.4 Phase I 177

9.1.5 Phase II 184

9.1.6 Phase III 190

9.1.7 Pre-registration 191

9.2 Summary of Multi-scenario Market Forecasts to 2022 192

9.2.1 Asia-Pacific 192

9.2.2 India 192

9.2.3 China 192

9.2.4 Australia 193

9.2.5 South Korea 193

9.2.6 Japan 193

9.3 Bibliography 194

9.4 Abbreviations 207

9.5 Research Methodology 211

9.5.1 Secondary Research 211

9.5.2 Marketed Product Profiles 212

9.5.3 Late-Stage Pipeline Candidates 212

9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 212

9.5.5 Product Competitiveness Framework 212

9.5.6 Pipeline Analysis 212

9.5.7 Forecasting Model 213

9.5.8 Deals Data Analysis 214

9.6 Contact Us 215

9.7 Disclaimer 215

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards